Q4 Earnings Forecast for Moderna Issued By Leerink Partnrs

Moderna, Inc. (NASDAQ:MRNA) – Stock analysts at Leerink Partnrs issued their Q4 2025 earnings estimates for shares of Moderna in a research report issued to clients and investors on Monday, January 13th. Leerink Partnrs analyst M. Foroohar forecasts that the company will post earnings of ($2.54) per share for the quarter. The consensus estimate for Moderna’s current full-year earnings is ($9.30) per share. Leerink Partnrs also issued estimates for Moderna’s FY2028 earnings at ($2.70) EPS and FY2029 earnings at ($0.07) EPS.

MRNA has been the topic of several other research reports. Needham & Company LLC reiterated a “hold” rating on shares of Moderna in a research report on Friday, November 8th. UBS Group lowered their target price on shares of Moderna from $108.00 to $96.00 and set a “buy” rating for the company in a report on Wednesday, January 8th. Sanford C. Bernstein initiated coverage on Moderna in a report on Thursday, October 17th. They set a “market perform” rating and a $55.00 price objective for the company. Argus downgraded shares of Moderna from a “buy” rating to a “hold” rating in a research note on Wednesday, December 18th. Finally, Berenberg Bank started coverage on Moderna in a report on Tuesday, November 19th. They issued a “hold” rating and a $42.00 price objective for the company. Four investment analysts have rated the stock with a sell rating, thirteen have issued a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $76.68.

Moderna Stock Up 0.9 %

MRNA opened at $34.77 on Wednesday. The company has a debt-to-equity ratio of 0.05, a quick ratio of 4.20 and a current ratio of 4.39. The firm’s fifty day moving average is $41.44 and its 200 day moving average is $67.56. The stock has a market cap of $13.38 billion, a price-to-earnings ratio of -5.97 and a beta of 1.60. Moderna has a fifty-two week low of $31.94 and a fifty-two week high of $170.47.

Moderna (NASDAQ:MRNA) last announced its earnings results on Thursday, November 7th. The company reported $0.03 EPS for the quarter, topping analysts’ consensus estimates of ($1.89) by $1.92. The company had revenue of $1.90 billion for the quarter, compared to analysts’ expectations of $1.25 billion. Moderna had a negative return on equity of 17.68% and a negative net margin of 43.77%. Moderna’s revenue for the quarter was up 3.8% compared to the same quarter last year. During the same period last year, the firm earned ($1.39) EPS.

Institutional Trading of Moderna

Hedge funds and other institutional investors have recently made changes to their positions in the company. State Street Corp boosted its position in shares of Moderna by 12.1% during the 3rd quarter. State Street Corp now owns 16,847,212 shares of the company’s stock worth $1,125,899,000 after purchasing an additional 1,823,276 shares in the last quarter. Geode Capital Management LLC raised its position in Moderna by 2.6% during the third quarter. Geode Capital Management LLC now owns 7,069,580 shares of the company’s stock worth $470,670,000 after acquiring an additional 178,115 shares during the last quarter. Wellington Management Group LLP raised its position in shares of Moderna by 21.0% during the 3rd quarter. Wellington Management Group LLP now owns 5,224,685 shares of the company’s stock worth $349,166,000 after purchasing an additional 906,114 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in shares of Moderna by 0.5% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 3,890,812 shares of the company’s stock worth $260,023,000 after acquiring an additional 19,819 shares during the last quarter. Finally, The Manufacturers Life Insurance Company lifted its holdings in Moderna by 6.2% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 3,073,934 shares of the company’s stock valued at $205,431,000 after purchasing an additional 178,939 shares in the last quarter. Hedge funds and other institutional investors own 75.33% of the company’s stock.

Insiders Place Their Bets

In other Moderna news, insider Shannon Thyme Klinger sold 1,418 shares of the stock in a transaction that occurred on Friday, November 29th. The stock was sold at an average price of $42.79, for a total transaction of $60,676.22. Following the completion of the sale, the insider now directly owns 19,717 shares of the company’s stock, valued at approximately $843,690.43. This trade represents a 6.71 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders sold a total of 2,664 shares of company stock worth $115,210 over the last 90 days. Corporate insiders own 15.70% of the company’s stock.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.